Found: 1
Select item for more details and to access through your institution.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
- Published in:
- NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00662-6
- By:
- Publication type:
- Article